
<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/joey/Project/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<encodingDesc>
			<appInfo>
				<application version="0.4.2-SNAPSHOT" ident="GROBID" when="2017-08-10T23:35+0000">
					<ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
				</application>
			</appInfo>
		</encodingDesc>
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Genome analysis Bioinformatics challenges for personalized medicine</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2011">2011</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName>
								<forename type="first">Guy</forename>
								<forename type="middle">Haskin</forename>
								<surname>Fernald</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="department">Biomedical Informatics Training Program</orgName>
								<orgName type="institution">Stanford University School of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Emidio</forename>
								<surname>Capriotti</surname>
							</persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Bioengineering</orgName>
								<orgName type="institution">Stanford University</orgName>
								<address>
									<settlement>Stanford</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Mathematics and Computer Science</orgName>
								<orgName type="institution" key="instit1">University of Balearic Islands</orgName>
								<orgName type="institution" key="instit2">Palma de Mallorca</orgName>
								<address>
									<settlement>Spain</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Roxana</forename>
								<surname>Daneshjou</surname>
							</persName>
							<affiliation key="aff3">
								<orgName type="institution">Stanford University School of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Konrad</forename>
								<forename type="middle">J</forename>
								<surname>Karczewski</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="department">Biomedical Informatics Training Program</orgName>
								<orgName type="institution">Stanford University School of Medicine</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Genetics</orgName>
								<orgName type="institution">Stanford University</orgName>
								<address>
									<settlement>Stanford</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Russ</forename>
								<forename type="middle">B</forename>
								<surname>Altman</surname>
							</persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Bioengineering</orgName>
								<orgName type="institution">Stanford University</orgName>
								<address>
									<settlement>Stanford</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Genetics</orgName>
								<orgName type="institution">Stanford University</orgName>
								<address>
									<settlement>Stanford</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Genome analysis Bioinformatics challenges for personalized medicine</title>
					</analytic>
					<monogr>
						<title level="j" type="main">REVIEW</title>
						<imprint>
							<biblScope unit="volume">27</biblScope>
							<biblScope unit="issue">13</biblScope>
							<biblScope unit="page" from="1741" to="1748"/>
							<date type="published" when="2011">2011</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1093/bioinformatics/btr295</idno>
					<note type="submission">Received on February 17, 2011; revised on April 28, 2011; accepted on May 4, 2011</note>
					<note>[14:52 3/6/2011 Bioinformatics-btr295.tex] Page: 1741 1741–1748 BIOINFORMATICS Associate Editor: Jonathan Wren Contact: russ.altman@stanford.edu Supplementary information: Supplementary data are available at Bioinformatics online.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<abstract>
				<p>Motivation: Widespread availability of low-cost, full genome sequencing will introduce new challenges for bioinformatics. Results: This review outlines recent developments in sequencing technologies and genome analysis methods for application in personalized medicine. New methods are needed in four areas to realize the potential of personalized medicine: (i) processing large-scale robust genomic data; (ii) interpreting the functional effect and the impact of genomic variation; (iii) integrating systems data to relate complex genetic interactions with phenotypes; and (iv) translating these discoveries into medical practice.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">INTRODUCTION</head><p>We are on the verge of the genomic era: doctors and patients will have access to genetic data to customize medical treatment. Consumers can already get 500 000–1 000 000 variant markers analyzed with associated trait information (<ref type="bibr" target="#b52">Hindorff et al., 2009</ref>), and soon full genome sequencing will cost less than $1000 (<ref type="bibr" target="#b32">Drmanac et al., 2010</ref>). One group has performed a complete clinical assessment of a patient using a personal genome (<ref type="bibr" target="#b5">Ashley et al., 2010</ref>), and the 1000 Genomes Project is sequencing 1000 individuals (1000 Genomes<ref type="bibr" target="#b47">Project Consortium et al., 2010</ref>). In the coming years, the bioinformatics world will be inundated with individual genomic data. This flood of data introduces significant challenges that the bioinformatics community needs to address. This review outlines the developments that led to these challenges, the previous work that can address them and the need for new methods to address them. The challenges fall into four main areas:</p><p>(i) processing large-scale robust genomic data; (ii) interpreting the functional impacts of genomic variation; (iii) integrating data to relate complex interactions with phenotypes; and (iv) translating these discoveries into medical practices. * To whom correspondence should be addressed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">THE PROMISE OF PERSONALIZED MEDICINE</head><p>In the last decade, molecular science has made many advances to benefit medicine, including the Human Genome project, International HapMap project and genome wide association studies (GWASs) (<ref type="bibr">International HapMap Consortium, 2005</ref>). Single nucleotide polymorphisms (SNPs) are now recognized as the main cause of human genetic variability and are already a valuable resource for mapping complex genetic traits (<ref type="bibr" target="#b23">Collins et al., 1997</ref>). Thousands of DNA variants have been identified that are associated with diseases and traits (<ref type="bibr" target="#b52">Hindorff et al., 2009</ref>). By combining these genetic associations with phenotypes and drug response, personalized medicine will tailor treatments to the patients' specific genotype (<ref type="figure" target="#fig_0">Fig. 1</ref>). Although whole genome sequences are not used in regular practice today (<ref type="bibr" target="#b72">McGuire and Burke, 2008</ref>), there are already many examples of personalized medicine in current practice. Chemotherapy medications such as trastuzumab and imatinib target © The Author(s) 2011. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page: 1742 1741–1748</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>G.H.Fernald et al.</head><p>specific cancers (<ref type="bibr" target="#b41">Gambacorti-Passerini, 2008;</ref><ref type="bibr" target="#b54">Hudis, 2007</ref>), a targeted pharmacogenetic dosing algorithm is used for warfarin (International Warfarin<ref type="bibr" target="#b55">Pharmacogenetics Consortium et al., 2009;</ref><ref type="bibr" target="#b92">Sagreiya et al., 2010</ref>) and the incidence of adverse events is reduced by checking for susceptible genotypes for drugs like abacavir, carbamazepine and clozapine (<ref type="bibr" target="#b30">Dettling et al., 2007;</ref><ref type="bibr" target="#b35">Ferrell and McLeod, 2008;</ref><ref type="bibr" target="#b50">Hetherington et al., 2002</ref>). Despite all of these advances, many challenges need to be addressed to make personalized medicine a reality. Today, a patient's genetics are consulted only for a few diagnoses and treatment plans and only in certain medical centers. Even if doctors had access to their patients' genomes today, only a small percentage of the genome could even be used (<ref type="bibr" target="#b128">Yngvadottir et al., 2009</ref>). Many of the annotations come from association studies, which tend to identify variants with small effect sizes and have limited applications for healthcare (<ref type="bibr" target="#b74">Moore et al., 2010</ref>). By addressing the challenges outlined in this review, bioinformatics will create the tools to tailor medical care to each individual genome, rather than rely on blanket therapies (<ref type="bibr" target="#b44">Ginsburg and Willard, 2009</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">CHALLENGE 1: PROCESSING LARGE-SCALE ROBUST GENOMIC DATA</head><p>Sequencing technologies are becoming affordable and are replacing the microarray-based genotyping methods, which were limited to interrogating regions of known variation (<ref type="bibr" target="#b78">Ng et al., 2010</ref>). Now a whole genome or a few dozen exomes can be sequenced in &lt;2 weeks with an error rate of ∼ 1 error per 100 kb (<ref type="bibr" target="#b32">Drmanac et al., 2010</ref>). Even such low error rates can lead to a significant number of errors; a 3 GB human genome would have ∼30 000 erroneous variant calls. The error rate from these technologies is a source of significant challenges in applications, including discovering novel variants. Each newly sequenced genome is expected to have between 100 000 and 300 000 previously undiscovered SNPs and &lt;1000 somatic mutations per generation (1000 Genomes<ref type="bibr" target="#b47">Project Consortium et al., 2010</ref>). The number of expected mutations may decrease as new genomes are sequenced; however, such a high number of errors turns variant discovery into a 'needle in a haystack' problem. Whenever a novel variant is identified, it will still have to be verified due to this false positive rate. In addition, other classes of variation, such as short insertion–deletion variants (indels), as well as copy number variants (CNVs) and structural variants (SVs), are even more difficult to detect using high-throughput sequencing. New algorithms for calling indels, CNVs and SVs from read data will be crucial in detecting these types of variations for clinical applications. Even high-quality sequence reads must be placed into their genomic context to identify variants, which is an active area of research since, for example, different mapping and alignment algorithms often yield different results. Because de novo assembly (<ref type="bibr" target="#b98">Shendure and Ji, 2008</ref>) is slow and complicated by repetitive elements, sequences are usually mapped to a genomic reference sequence instead. Algorithms such as BLAST (<ref type="bibr" target="#b2">Altschul et al., 1990</ref>) or Smith–Waterman (<ref type="bibr" target="#b102">Smith and Waterman, 1981</ref>) have been traditionally used, but their execution speed depends on the genome size. While individual queries may only take seconds per CPU, aligning 100 million of them would require more than 3 CPU years. As a result, new algorithms are being developed to address this problem. BLAT is similar to standard sequence alignment, but also incorporates an indexed version of the genome instead of linear search (<ref type="bibr" target="#b62">Kent, 2002</ref>). Many packages like BLAT have been optimized for the alignment of short reads by using hashing, prefix and suffix trees or other heuristics (<ref type="bibr" target="#b67">Li and Homer, 2010</ref>). BWA, used for the 1000 Genomes Project, is highly accurate with &lt;0.1% errors for simulated data and can map ∼ 7 GB of short reads per CPU day (<ref type="bibr" target="#b66">Li and Durbin, 2009;</ref><ref type="bibr" target="#b67">Li and Homer, 2010</ref>). To achieve the standard 30X coverage would still require 13 CPU days and so is ideally performed on a cluster or by using a cloud computing environment (<ref type="bibr" target="#b33">Dudley and Butte, 2010</ref>), which can be used for efficient computational analysis of secure clinical data. A remaining challenge for short read assemblers is reference sequence bias: reads that more closely resemble the reference sequence are more likely to successfully map as compared with reads that contain valid mismatches. Proper care must be taken to avoid errors in these alignments, and is discussed in a recent review (<ref type="bibr" target="#b83">Pool et al., 2010</ref>). There is an inherent trade-off in allowing mismatches: the program must allow for mismatches without resulting in false alignments. Reference sequence bias is important when making heterozygous SNP calls and when analyzing allelespecific expression using RNA-Seq data (<ref type="bibr" target="#b28">Degner et al., 2009</ref>). The problem is exacerbated with longer reads: allowing for one mismatch per read is acceptable for 35 bp reads, but insufficient for 100 bp reads. When the diploid sequence is known, reference sequence bias can be avoided by mapping the reads to both strands, as can be done when mapping RNA-Seq reads to a sequenced genome. An alternative approach is to use ambiguous base codes to avoid the requirement of storing redundant sequences, such as with MOSAIK, developed by the Marth Lab (Michael Stromberg, Boston University). Using this approach, a C/T SNP can be represented as Y. This representation increases the storage requirements: because the genome is often stored in a hashed data structure, the number of keys and mappings increases to accommodate the new codes. Another challenge is developing new methods for novel SNP discovery: while the calling of common variants can be aided by their presence in a database such as dbSNP, accurate detection of rare and novel variants will require increased confidence in the SNP call. De novo alignment methods require too much computation time to be feasible and reference alignment methods are biased. The challenge is to develop new algorithms that are computationally tractable and still avoid reference sequence bias. Finally, there is a pressing need to improve quality control metrics. We can judge mapping and SNP call qualities by the ratio of transition (purine/purine or pyrimidine/pyrimidine) substitutions to transversion (purine/pyrimidine) substitutions. These ratios were established during previous sequencing efforts and we expect to see similar ratios (∼2–2.1) for newly human genomes (<ref type="bibr" target="#b132">Zhang and Gerstein, 2003</ref>). When working with genomes from families, we can estimate errors with the Mendelian inheritance error (MIE) rate: impossible combinations of inheritance most likely represent errors (<ref type="bibr" target="#b34">Ewen et al., 2000</ref>). Transition/transversion ratio and MIE metrics are useful for measuring the quality of a dataset and are used by most large projects, such as the 1000 Genomes project (1000 Genomes<ref type="bibr" target="#b47">Project Consortium et al., 2010</ref>). At the individual SNP level, we must rely on relative quality scores, so in order to confidently identify novel variants we must be verify them with an independent Page: 1743 1741–1748method. Variants can be validated with targeted resequencing or genotyping arrays. Alternatively, whole genome resequencing by an orthogonal sequencing platform can be performed, but is expensive and time consuming.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bioinformatics challenges for personalized medicine</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">CHALLENGE 2: INTERPRETATION OF THE FUNCTIONAL EFFECT AND THE IMPACT OF GENOMIC VARIATION</head><p>After genomic data has been processed, the functional effect and the impact of the genetic variations must be analyzed. Genome-wide association studies (GWASs) have been used to assess the statistical associations of SNPs with many important common diseases (WTCC). These methods are providing new insights, but only a limited number of variants have been characterized, and understanding the functional relationship between associated variants and phenotypic traits has been difficult (<ref type="bibr" target="#b38">Frazer et al., 2009</ref>). In the strictest definition, a SNP is a single nucleotide variant where the allele frequency in the human population is higher then 1%. In this review, we use the term SNP in a broader sense to also include rare variants that occur in a smaller fraction of the population. Important issues for predicting the impact of SNPs are data management, retrieval and quality control. During the last few years, the number of known SNPs has increased at an exponential rate (<ref type="figure" target="#fig_2">Fig. 2</ref>). The dbSNP database (<ref type="bibr" target="#b99">Sherry et al., 2001</ref>The SwissVar is a database of manually annotated missense SNPs (mSNPs) and contains 56 000 mSNPs from &gt;11 000 genes. Another important resource for SNP data is the Online Mendelian Inheritance in Man (OMIM) database (<ref type="bibr" target="#b3">Amberger et al., 2009</ref>) of human SNPs and their associations with Mendelian disorders. The PharmGKB database contains manually curated associations between genes and drugs and a catalog of genetic variations with known impact on drug response, including &gt;40 very important pharmacogenes (VIPs) and over 3400 annotated drug–response variants. The Catalogue of Somatic Mutations in Cancer (COSMIC) at the Sanger Institute stores ∼25 000 unique mutations somatic mutation data related to human cancer extracted from the literature. A selection of the most significant SNP data sources is reported in Supplementary Table S1. In the last few years, several computational methods have been developed to predict deleterious missense SNPs (<ref type="bibr" target="#b57">Karchin, 2009;</ref><ref type="bibr" target="#b73">Mooney, 2005;</ref><ref type="bibr" target="#b107">Tavtigian et al., 2008</ref>). These methods have used different approaches such as empirical rules (<ref type="bibr" target="#b77">Ng and Henikoff, 2003;</ref><ref type="bibr" target="#b85">Ramensky et al., 2002</ref>), Hidden Markov Models (HMMs) (<ref type="bibr" target="#b108">Thomas and Kejariwal, 2004</ref>), Neural Networks (<ref type="bibr" target="#b11">Bromberg et al., 2008;</ref><ref type="bibr" target="#b36">Ferrer-Costa et al., 2005</ref>), Decision Trees (<ref type="bibr" target="#b31">Dobson et al., 2006;</ref><ref type="bibr" target="#b64">Krishnan and Westhead, 2003</ref>), Random Forests (<ref type="bibr" target="#b8">Bao and Cui, 2005;</ref><ref type="bibr" target="#b18">Carter et al., 2009;</ref><ref type="bibr" target="#b56">Kaminker et al., 2007;</ref><ref type="bibr" target="#b66">Li et al., 2009;</ref><ref type="bibr" target="#b115">Wainreb et al., 2010</ref>) and Support Vector Machines (<ref type="bibr" target="#b13">Calabrese et al., 2009;</ref><ref type="bibr" target="#b16">Capriotti et al., 2006</ref><ref type="bibr" target="#b17">Capriotti et al., , 2008</ref><ref type="bibr" target="#b58">Karchin et al., 2005;</ref><ref type="bibr" target="#b130">Yue and Moult, 2006</ref>). The prediction algorithms input features generally include amino acid sequence, protein structure and evolutionary information. The amino acid sequence features rely on the physicochemical properties of the mutated residues such as hydrophobicity, charge, polarity and bulkiness. Protein structural information describes the structural environment of the mutation and has been successfully used to predict the protein stability change upon mutation (<ref type="bibr" target="#b14">Capriotti et al., 2004</ref><ref type="bibr" target="#b15">Capriotti et al., , 2005</ref><ref type="bibr" target="#b97">Schymkowitz et al., 2005;</ref><ref type="bibr" target="#b133">Zhou and Zhou, 2002</ref>). Some of the most important features for the prediction of the impact of missense SNPs are derived from evolutionary analysis: critical amino acids are often conserved in protein families and so changes at conserved positions tend to be deleterious. New algorithms that include knowledge-based information are being developed (<ref type="bibr" target="#b1">Alexiou et al., 2009;</ref><ref type="bibr" target="#b13">Calabrese et al., 2009;</ref><ref type="bibr" target="#b56">Kaminker et al., 2007</ref>). Methods based on evolutionary information for the prediction of mSNPs include SIFT (<ref type="bibr" target="#b77">Ng and Henikoff, 2003</ref>) and PolyPhen (<ref type="bibr" target="#b85">Ramensky et al., 2002</ref>). SIFT scores the normalized probabilities for all possible substitutions using a multiple sequence alignment between homolog proteins, and PolyPhen predicts the impact of mSNPs using different sequence-based features and a position-specific independent counts (PSICs) matrix from multiple sequence alignment. The PANTHER algorithm (<ref type="bibr" target="#b109">Thomas et al., 2003</ref>) uses a library of protein family hidden Markov models to predict deleterious mutations. Recent work shows that 3D structural features improve the prediction of disease-related mSNPs (<ref type="bibr" target="#b8">Bao and Cui, 2005;</ref><ref type="bibr" target="#b58">Karchin et al., 2005;</ref><ref type="bibr" target="#b130">Yue and Moult, 2006</ref>). Knowledgebased information has been used to increase the accuracy of prediction algorithms to over 80%. For example, SNPs&amp;GO (<ref type="bibr" target="#b13">Calabrese et al., 2009</ref>) is an algorithm based on functional information that takes in input log-odd scores calculated using Gene Ontology (GO) annotation terms. MutPred (<ref type="bibr" target="#b66">Li et al., 2009</ref>) evaluates the probabilities of gain or loss of structure and function upon mutations and predicts their impact using a Random Forest-based Page: 1744 1741–1748</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>G.H.Fernald et al.</head><p>approach. Selected methods for the prediction of deleterious mSNPs are listed in Supplementary Table S2 and more details about mSNP predictors have been recently reviewed (<ref type="bibr" target="#b22">Cline and Karchin, 2011;</ref><ref type="bibr" target="#b111">Thusberg et al., 2011</ref>) Prediction methods do not provide any information about the pathophysiology of the diseases and so experimental tests are required to validate genetic predictions. Laboratory validation is expensive and time consuming and so there is a need for fast and accurate methods for gene prioritization. Currently, the most effective strategy uses the concept of similarity to genes that are linked to the biological process of interest (guilt-by-association). The input data for the available gene prioritization methods are derived from functional annotation, protein–protein interaction (PPI) data, biological pathways and literature. The SUSPECT algorithm prioritizes genes by comparing sequence features, gene expression data, Interpro domains and functional terms (<ref type="bibr" target="#b0">Adie et al., 2006</ref>). ToppGene combines mouse phenotype data with human gene annotations and literature. MedSim uses functional information from human disease genes or proteins and their orthologs in mouse models (<ref type="bibr" target="#b96">Schlicker et al., 2010</ref>). ENDEAVOUR is trained on genes involved in a known biological process and ranks candidate genes after considering several genomic data sources (<ref type="bibr" target="#b113">Tranchevent et al., 2008</ref>). G2D prioritization strategy is based on a combination of data mining on biomedical databases and sequence features (<ref type="bibr" target="#b82">Perez-Iratxeta et al., 2005</ref>). PolySearch analyzes biomedical databases to build relationships between diseases, genes, mutations, drugs, pathways, tissues, organs and metabolites in humans (<ref type="bibr" target="#b21">Cheng et al., 2008</ref>). MimMiner ranks phenotypes using text mining by comparing the human phenome and disease phenotypes (van<ref type="bibr" target="#b114">Driel et al., 2006</ref>). PhenoPred detects gene–disease associations using the human PPI network, known gene–disease associations, protein sequences and protein functional information at the molecular level (<ref type="bibr" target="#b84">Radivojac et al., 2008</ref>). GeneMANIA (<ref type="bibr" target="#b4">Andersen et al., 2008</ref>) generates hypotheses about gene function, analyzing gene lists and prioritizing genes for functional assays. The method takes in input genes from six organisms and analyzes them using information from different general and organism-specific functional genomics datasets. For more details about gene prioritizing tools, a recently published review (<ref type="bibr" target="#b112">Tranchevent et al., 2010</ref>) and the Gene Prioritization Portal provide comprehensive descriptions of available predictors. The methods for the analysis of SNPs are mainly limited to the prediction of the impact of missense SNPs. New methods are needed to evaluate the impact of insertion, deletion and synonymous SNPs. In addition, there is a need to detect functional regions in the genome so that the effect of intronic SNPs can be analyzed, such as those in promoter regions and splicing sites. For noncoding regions, conservation across species is more difficult to detect. Fortunately, with the fast growth of functionally annotated genomes our ability to predict the impact of non-coding variants will increase. For example, SNPs occurring in transcriptional motifs can affect transcription factor binding, which suggests functional consequences for variants in regulatory regions (<ref type="bibr" target="#b59">Kasowski et al., 2010</ref>). Recently, a method to identify possible genetic variations in regulatory regions (is-rSNP) has been developed (<ref type="bibr" target="#b4">Andersen et al., 2008</ref>). Is-rSNP combines phylogenetic information and transcription factor binding site prediction to identify variation in candidate cisregulatory elements. The detection of variants affecting splicing site is also an important task. The Skippy algorithm (<ref type="bibr" target="#b121">Woolfe et al., 2010</ref>) analyzes the genomic region surrounding the variant to predict severe effects on gene function through disruption of splicing. A more exhaustive description of the methods for the prediction of deleterious variants in non-coding has been recently published (<ref type="bibr" target="#b22">Cline and Karchin, 2011</ref>). Last year, the first edition of the Critical Assessment of Genome Interpretation (CAGI) was organized to assess the available methods for predicting phenotypic impact of genomic variation and to stimulate future research. In the first year of CAGI (http://genomeinterpretation.org/), the organizers provided six different sets of data for six different tasks. The majority of the participating groups submitted predictions for just two classes of experiments related to the detection of disease-related and functionmodifying variants. A few groups submitted predictions for the other categories: evaluation of risky SNPs from GWAS studies, interpretation of the Personal Genome Project data, prediction of mutations to P53 function and the response of breast cancer cell lines to different drugs. Several available predictors performed well for disease and functional predictions and there were promising results in the other categories. In the future, competitions such as CAGI will improve the quality of the available prediction methods and will renew the challenge for the understanding of genomic variation data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">CHALLENGE 3: INTEGRATING SYSTEMS AND DATA TO CAPTURE COMPLEXITY</head><p>Given the complex phenotypes involved in personalized medicine, the simple 'one-SNP, one-phenotype' approach taken by most studies is insufficient. Most medically relevant phenotypes are thought to be the result of gene–gene and gene–environment interactions (<ref type="bibr" target="#b71">Manolio et al., 2009</ref>). For example, drug response often depends on multiple pharmacokinetic and pharmacodynamic interactions, which form a robust and tolerant system with highly polymorphic enzymes and many interaction partners (<ref type="bibr" target="#b119">Wilke et al., 2005</ref>). As a result of this complexity, a drug–response phenotype of interest is likely to depend on many genes and environmental factors. Basic GWAS approaches for pharmacogenomics have had some success, including studies of warfarin that have linked the majority of variation in response to just two genes, CYP2C9 and VKORC1 (<ref type="bibr" target="#b69">Limdi and Veenstra, 2008</ref>). These and other studies of warfarin have even led to an improved dosing algorithm with improvements over the traditional clinical algorithm (International<ref type="bibr" target="#b55">Warfarin Pharmacogenetics Consortium et al., 2009</ref>). Clopidogrel response has similarly been associated with variants of CYP2C19 (). Despite this success, there is debate over whether or not traditional techniques will be successful for pharmacogenomics. There is concern that pharmacogenomics GWAS themselves are susceptible to many limitations: insufficient sample size, selection biases for genetic variants, environmental interactions that may affect the outcome measures and multiple gene–gene interactions that may underlie unexplained effects (<ref type="bibr" target="#b76">Motsinger-Reif et al., 2010</ref>). These limitations become particularly difficult when researching rare events such as the pharmacogentics of adverse events. The methods for GWAS are designed for single marker associations and are known to have limitations in explaining the heritability of disease (<ref type="bibr" target="#b71">Manolio et al., 2009</ref>). It is unlikely that Page: 1745 1741–1748</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bioinformatics challenges for personalized medicine</head><p>these same methods will do any better with pharmacogenetics. In fact, if these methods are parameterized for the multiple-marker associations necessary for pharmacogenetics, then they will suffer from the 'curse of dimensionality' and lose a significant amount of statistical power (<ref type="bibr" target="#b9">Bellman and Kalaba, 1959</ref>). For example, to evaluate all combinations of two SNPs for 1 million SNPs in a genome requires examining nearly 500 billion possibilities. The challenge for bioinformatics is to address this complexity by developing methods that combine multiple data sources without losing statistical power. Several groups have already tried to deal with this kind of complexity in GWAS for disease (<ref type="bibr" target="#b75">Motsinger et al., 2007</ref>). Exhaustive search (<ref type="bibr" target="#b105">Storey et al., 2005</ref>) and forward search () have both been applied; however, the former can still lose statistical power and the later may miss some associations. Model selection methods have been successful with disease and trait GWAS studies by using selection techniques to choose multifactorial models that balance the false positive rate, statistical power and computational requirements of the search (<ref type="bibr" target="#b65">Lee et al., 2008;</ref><ref type="bibr" target="#b122">Wray et al., 2007;</ref><ref type="bibr" target="#b124">Wu and Zhao, 2009</ref>). Given the size of the genomic datasets, dimensionality reduction methods such as principal components analysis, information gain and multifactor dimensionality reduction will be essential to make complexity algorithms tractable (<ref type="bibr" target="#b48">Hahn et al., 2003;</ref><ref type="bibr" target="#b104">Statnikov et al., 2005;</ref><ref type="bibr" target="#b126">Yeung and Ruzzo, 2001</ref>). Some of these methods have proven successful for finding multilocus associations with diseases such as hypertension and familial amyloid polyneuropathy type I (<ref type="bibr" target="#b103">Soares et al., 2005;</ref><ref type="bibr" target="#b120">Williams et al., 2004</ref>). Many more feature selection techniques for bioinformatics are classified and discussed in a recent review (<ref type="bibr" target="#b91">Saeys et al., 2007</ref>). These methods can be very effective when dealing with large datasets; however, they do not integrate with any external knowledge sources or inform the biology behind the interactions. Systems biology and network approaches address to the problem of complexity by integrating molecular data at multiple levels of biology including genomes, transcriptomes, metabolomes, proteomes and functional and regulatory networks (<ref type="bibr" target="#b63">Kohl et al., 2010</ref>). We can view a disease or a drug–response phenotype as a global perturbation of networks from their stable state (<ref type="bibr" target="#b7">Auffray et al., 2009</ref>). This approach integrates biological knowledge from networks to make inferences about what genes or combinations of genes and other biological markers are more likely to be associated. Combining disparate data sources can result in novel associations and provide insight into gene–gene and gene–environment interactions. One group created a disease–gene network by combining the diseases and associated genes available in OMIM (<ref type="bibr" target="#b45">Goh et al., 2007</ref>). Analyzing this network showed that disease genes are often non-essential and not necessarily hub genes. The same group created a drug–target network and integrated that network with a PPI network. The network shows that similar drugs cluster together, palliative and etiological drugs show different topologies, and newer and experimental drugs tend toward polypharmacology (<ref type="bibr" target="#b127">Yildirim et al., 2007</ref>). A global mapping of pharmacalogical space can be made using chemical structure, disease indication and protein sequence and can be used to make predictions of polypharmacology (<ref type="bibr" target="#b81">Paolini et al., 2006</ref>). Another suggestion is to integrate epigenetic information to further our understanding of drug phenotypes (<ref type="bibr" target="#b131">Zhang and Dolan, 2009</ref>). Pathway and gene set methods can also be applied to GWAS, where a set of genes is identified that is suspected to be associated. These methods are similar to Gene Set Enrichment Analysis (GSEA) for microarray expression data (<ref type="bibr" target="#b106">Subramanian et al., 2005</ref>). Usually a standard statistical test is used to determine if a set of genes is associated (<ref type="bibr" target="#b19">Chasman, 2008;</ref><ref type="bibr" target="#b116">Wang et al., 2007;</ref><ref type="bibr" target="#b129">Yu et al., 2009</ref>), but other more specialized metrics have been created. The SNP Ratio Test compares the number of SNPs in a pathway to permuted sets, and the Prioritizing Risk Pathways method combines pathway and genetic data into a single metric (<ref type="bibr" target="#b20">Chen et al., 2009;</ref><ref type="bibr" target="#b79">O'Dushlaine et al., 2009</ref>). Many groups hypothesize that the integrative approach of systems biology will successfully link genomic measurements with clinical applications (<ref type="bibr" target="#b6">Atkinson and Lyster, 2010;</ref><ref type="bibr" target="#b10">Berg et al., 2010;</ref><ref type="bibr" target="#b53">Hopkins, 2007</ref>). Indeed, one group has integrated chemical similarity metrics, pharmacogenomic interactions and PPI to predictive method for pharmacogenes (<ref type="bibr" target="#b49">Hansen et al., 2009</ref>). Another group has used similarity of drug ligand sets to predict and validate novel 'off-target' interactions (<ref type="bibr" target="#b60">Keiser et al., 2007</ref>). These systems approaches are encouraging, but bioinformaticians need to be careful of a few pitfalls as they proceed. Methods need to be based on high-quality data to avoid the 'garbage-in, garbageout' phenomenon, especially when one incorrect assumption can propagate through multiple data source and magnify the error. For example, transferring annotations based on similarity works sometimes, but could easily associate a paralog with an incorrect function. Chemical similarity poses the same risk; two similar molecules may behave very differently biochemically. Finally, assumptions must also be examined carefully; for example, a method that relates gene expression with drug targets must bear in mind that most drugs bind proteins, not DNA or RNA.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6">CHALLENGE 4: MAKING IT ALL CLINICALLY RELEVANT</head><p>The ultimate challenge for this research is to apply the results for improved patient care. Much of this research has yet to be translated to the clinic. In fact, many physicians are unprepared to incorporate personal genetic testing into their practice and it is unclear how to best apply research results to improve patient care (<ref type="bibr" target="#b72">McGuire and Burke, 2008</ref>). One of the areas where bioinformatics can have the greatest clinical impact is in pharmacogenomics. Most pharmaceutical development addresses medical problems with a 'one drug fits all' approach. Genetic variation has been shown to influence drug selection, dosing and adverse events (<ref type="bibr" target="#b43">Giacomini et al., 2007</ref>), and the therapeutic benefits of taking a genetically tailored approach to drug development is now recognized (<ref type="bibr" target="#b37">Foot et al., 2010;</ref><ref type="bibr" target="#b88">Roses, 2004</ref>). One study found that a hypothetical pharmacogenetically driven clinical trial of the anticoagulant warfarin could save up to 60% of the cost and reduce possible adverse events (<ref type="bibr" target="#b80">Ohashi and Tanaka, 2010</ref>). There are already many examples of drugs which have retrospectively been found to have strong pharmacogenomic interactions, including thiopurines for cancer (<ref type="bibr" target="#b117">Weinshilboum, 2001</ref>) and the anticoagulant clopiogrel (). A trial for using rosiglitazone, an approved Type II diabetes drug, for Alzheimer's disease is an early example of prospective application of pharmacogenomics. The hypothesis was that ApoE4 non-carriers would have a better response than ApoE4 carriers. Page: 1746 1741–1748</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>G.H.Fernald et al.</head><p>The initial Phase II pharmacogenetic-based results appeared to show that non-ApoE4 carriers showed improvement over placebo (<ref type="bibr" target="#b89">Roses, 2009</ref>). A later study of ApoE4-stratified patients showed no significant benefits; however, the idea of prospective gene-based stratification for drug trials still holds future promise (<ref type="bibr" target="#b46">Gold et al., 2010</ref>). Prospective gene-stratification hypotheses need to be generated for future trials and will require new bioinformatics methods (<ref type="bibr" target="#b89">Roses, 2009</ref>). Since new drugs will not have any known gene interactions, tools for predicting drug–target or drug–gene interactions will be essential (<ref type="bibr" target="#b49">Hansen et al., 2009;</ref><ref type="bibr" target="#b61">Keiser et al., 2009</ref>). Pharmacogenomics has already been successful in improving drug prescription and dosing. Most prescriptions are written with a 'one dose fits all' approach with adjustments based on gender, weight, liver and kidney functions or allergies. Some drugs have more laborious dosing calculations such as the anticoagulant warfarin (<ref type="bibr" target="#b39">Gage and Lesko, 2008;</ref><ref type="bibr" target="#b125">Wysowski et al., 2007</ref>). Warfarin dosing is traditionally determined by a time-intensive 'guess and test'method, until the coagulation tests stabilize. Pharmacogenomics identified several SNPs affecting dosing, includingCYP2C9 and VKORC1 (<ref type="bibr" target="#b51">Higashi et al., 2002;</ref><ref type="bibr" target="#b86">Rieder et al., 2005;</ref><ref type="bibr" target="#b90">Rost et al., 2004</ref>). Similar studies have been applied to clopidogrel, tramadol, anti-psychotics and many other drugs (<ref type="bibr" target="#b118">Wilffert et al., 2011</ref>). Ultimately, pharmacogenomic prescription and dosing algorithms need to be accessible to physicians, like the new warfarin dosing algorithms from the International Warfarin Pharmacogenomic Consortium (IWPC) (<ref type="bibr" target="#b55">International Warfarin Pharmacogenetics Consortium et al., 2009</ref>). Moreover, the current state of medical practice needs to be updated to include routine pharmacogenetic testing, educating and training physicians in personalized medicine, and further clinical trials to prove the efficacy of pharmacogeneticbased prescriptions. Bioinformatics also translates discoveries to the clinic by disseminating discoveries through curated, searchable databases like PharmGKB, dbGaP, PacDB and FDA AERS (<ref type="bibr" target="#b40">Gamazon et al., 2010;</ref><ref type="bibr" target="#b70">Mailman et al., 2007;</ref><ref type="bibr" target="#b110">Thorn et al., 2010</ref>). A major bottleneck for these databases is manual curation of the data. Biologically and medically focused text mining algorithms can speed the collection of this structured data, such as methods that use sentence syntax and natural language processing to derive drug–gene and gene–gene interactions from scientific literature (<ref type="bibr" target="#b27">Coulet et al., 2010;</ref><ref type="bibr" target="#b42">Garten et al., 2010</ref>). These databases and methods need to be developed and used carefully. All these data sources are susceptible to errors and so validation of data is essential, especially before the information is applied in the clinic. Finally, there are challenges and opportunities for bioinformatics to integrate with the electronic medical record (EMR) (<ref type="bibr" target="#b12">Busis, 2010</ref>). For example, the BioBank system at Vanderbilt links patient DNA with a deidentified EMRs to provide a rich research database for additional translational research in disease–gene and drug–gene associations (<ref type="bibr" target="#b29">Denny et al., 2010;</ref><ref type="bibr" target="#b87">Roden et al., 2008</ref>). Some health care companies and HMOs have also begun to collect genetic information from their patients. In order to even implement such genome-based systems, the medical infrastructure will have to shift from paper to electronic medical records, in order to be compatible with bioinformatics portals for data delivery and interpretation. Ultimately, bioinformatics needs to develop methods that interrogate the genome in the clinic and allow physicians to use personalized medicine in their daily practice.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig.1.</head><figDesc>Fig. 1. Personalized medicine. Personal genomics connect genotype to phenotype and provide insight into disease. Pharmacogenomics connect connects genotype to patient-specific treatment. Traditional medicine defines the pathologic states and clinical observations to evaluate and adjust treatments.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><figDesc>[14:52 3/6/2011 Bioinformatics-btr295.tex]</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig.2.</head><figDesc>Fig. 2. Number of validated human SNPs in dbSNP overtime.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><figDesc>) is the most comprehensive repository of SNPs data from different organisms. At the time of writing this review, the database contains about 20 million validated human SNPs (Build 132, September 2010). The Human Gene Mutation Database (HGMD) is a comprehensive collection of germline mutations in genes that are associated with human inherited diseases. The free version for academic and nonprofit users contains more than 76 000 mutations from ∼2900 genes.</figDesc></figure>

			<note place="foot">at :: on August 30, 2016 http://bioinformatics.oxfordjournals.org/ Downloaded from</note>
		</body>
		<back>

			<div type="acknowledgement">
			</div>

			<div type="references">

				<listBibl>

<biblStruct   xml:id="b0">
	<analytic>
		<title level="a" type="main">SUSPECTS: enabling fast and effective prioritization of positional candidates</title>
		<author>
			<persName>
				<forename type="first">E</forename>
				<forename type="middle">A</forename>
				<surname>Adie</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="773" to="774" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b1">
	<analytic>
		<title level="a" type="main">Lost in translation: an assessment and perspective for computational microRNA target identification</title>
		<author>
			<persName>
				<forename type="first">P</forename>
				<surname>Alexiou</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="3049" to="3055" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b2">
	<analytic>
		<title level="a" type="main">Basic local alignment search tool</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<forename type="middle">F</forename>
				<surname>Altschul</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Mol. Biol</title>
		<imprint>
			<biblScope unit="volume">215</biblScope>
			<biblScope unit="page" from="403" to="410" />
			<date type="published" when="1990" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b3">
	<analytic>
		<title level="a" type="main">McKusick&apos;s Online Mendelian Inheritance in Man (OMIM)</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<surname>Amberger</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="793" to="800" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b4">
	<analytic>
		<title level="a" type="main">In silico detection of sequence variations modifying transcriptional regulation</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">C</forename>
				<surname>Andersen</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Comput. Biol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">5</biblScope>
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b5">
	<analytic>
		<title level="a" type="main">Clinical assessment incorporating a personal genome</title>
		<author>
			<persName>
				<forename type="first">E</forename>
				<forename type="middle">A</forename>
				<surname>Ashley</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="1525" to="1535" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b6">
	<analytic>
		<title level="a" type="main">Systems clinical pharmacology</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Atkinson</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">P</forename>
				<surname>Lyster</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Pharmacol. Therap</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="3" to="6" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b7">
	<analytic>
		<title level="a" type="main">Systems medicine: the future of medical genomics and healthcare</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<surname>Auffray</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome</title>
		<imprint>
			<biblScope unit="issue">1 2</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b8">
	<analytic>
		<title level="a" type="main">Prediction of the phenotypic effects of non-synonymous single nucleotide polymorphisms using structural and evolutionary information</title>
		<author>
			<persName>
				<forename type="first">L</forename>
				<surname>Bao</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">Y</forename>
				<surname>Cui</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2185" to="2190" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b9">
	<analytic>
		<title level="a" type="main">A mathematical theory of adaptive control processes</title>
		<author>
			<persName>
				<forename type="first">R</forename>
				<surname>Bellman</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">R</forename>
				<surname>Kalaba</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proc. Natl Acad. Sci. USA</title>
		<meeting>. Natl Acad. Sci. USA</meeting>
		<imprint>
			<date type="published" when="1959" />
			<biblScope unit="page" from="1288" to="1290" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b10">
	<analytic>
		<title level="a" type="main">Systems biology and pharmacology</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<surname>Berg</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Pharmacol. Therap</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="17" to="19" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b11">
	<analytic>
		<title level="a" type="main">SNAP predicts effect of mutations on protein function</title>
		<author>
			<persName>
				<forename type="first">Y</forename>
				<surname>Bromberg</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2397" to="2398" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b12">
	<analytic>
		<title level="a" type="main">How can I choose the best electronic health record system for my practice?</title>
		<author>
			<persName>
				<forename type="first">N</forename>
				<forename type="middle">A</forename>
				<surname>Busis</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="60" to="64" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b13">
	<analytic>
		<title level="a" type="main">Functional annotations improve the predictive score of human disease-related mutations in proteins</title>
		<author>
			<persName>
				<forename type="first">R</forename>
				<surname>Calabrese</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Mutat</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1237" to="1244" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b14">
	<analytic>
		<title level="a" type="main">A neural-network-based method for predicting protein stability changes upon single point mutations</title>
		<author>
			<persName>
				<forename type="first">E</forename>
				<surname>Capriotti</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="63" to="68" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
	<note>Suppl. . 1</note>
</biblStruct>

<biblStruct   xml:id="b15">
	<analytic>
		<title level="a" type="main">) I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure</title>
		<author>
			<persName>
				<forename type="first">E</forename>
				<surname>Capriotti</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="306" to="310" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b16">
	<analytic>
		<title level="a" type="main">Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information</title>
		<author>
			<persName>
				<forename type="first">E</forename>
				<surname>Capriotti</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="2729" to="2734" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b17">
	<analytic>
		<title level="a" type="main">Use of estimated evolutionary strength at the codon level improves the prediction of disease-related protein mutations in humans</title>
		<author>
			<persName>
				<forename type="first">E</forename>
				<surname>Capriotti</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Mutat</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="198" to="204" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b18">
	<analytic>
		<title level="a" type="main">Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations</title>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Carter</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="6660" to="6667" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b19">
	<analytic>
		<title level="a" type="main">On the utility of gene set methods in genomewide association studies of quantitative traits</title>
		<author>
			<persName>
				<forename type="first">D</forename>
				<surname>Chasman</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genet. Epidemiol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="658" to="668" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b20">
	<analytic>
		<title level="a" type="main">Prioritizing risk pathways: a novel association approach to searching for disease pathways fusing SNPs and pathways</title>
		<author>
			<persName>
				<forename type="first">L</forename>
				<surname>Chen</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="237" to="242" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b21">
	<analytic>
		<title level="a" type="main">PolySearch: a web-based text mining system for extracting relationships between human diseases, genes, mutations, drugs and metabolites</title>
		<author>
			<persName>
				<forename type="first">D</forename>
				<surname>Cheng</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="399" to="405" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b22">
	<analytic>
		<title level="a" type="main">Using bioinformatics to predict the functional impact of SNVs</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">S</forename>
				<surname>Cline</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">R</forename>
				<surname>Karchin</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="441" to="448" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b23">
	<analytic>
		<title level="a" type="main">Variations on a theme: cataloging human DNA sequence variation</title>
		<author>
			<persName>
				<forename type="first">F</forename>
				<forename type="middle">S</forename>
				<surname>Collins</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">278</biblScope>
			<biblScope unit="page" from="1580" to="1581" />
			<date type="published" when="1997" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b24">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b25">
	<monogr>
		<title/>
		<author>
			<persName>
				<surname>Page</surname>
			</persName>
		</author>
		<imprint>
			<biblScope unit="page" from="1747" to="1741" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b26">
	<analytic>
		<title level="a" type="main">A second generation human haplotype map of over 3.1 million SNPs</title>
		<author>
			<persName>
				<forename type="first">I</forename>
				<forename type="middle">H</forename>
				<surname>Bioinformatics Challenges For Personalized Medicine Consortium</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">449</biblScope>
			<biblScope unit="page" from="851" to="861" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b27">
	<analytic>
		<title level="a" type="main">Using text to build semantic networks for pharmacogenomics</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Coulet</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biomed. Inform</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1009" to="1019" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b28">
	<analytic>
		<title level="a" type="main">Effect of read-mapping biases on detecting allele-specific expression from RNA-sequencing data</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">F</forename>
				<surname>Degner</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="3207" to="3212" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b29">
	<analytic>
		<title level="a" type="main">PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">C</forename>
				<surname>Denny</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1205" to="1210" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b30">
	<analytic>
		<title level="a" type="main">Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<surname>Dettling</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics J</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="325" to="332" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b31">
	<analytic>
		<title level="a" type="main">Predicting deleterious nsSNPs: an analysis of sequence and structural attributes</title>
		<author>
			<persName>
				<forename type="first">R</forename>
				<forename type="middle">J</forename>
				<surname>Dobson</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">217</biblScope>
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b32">
	<analytic>
		<title level="a" type="main">Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays</title>
		<author>
			<persName>
				<forename type="first">R</forename>
				<surname>Drmanac</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">327</biblScope>
			<biblScope unit="page" from="78" to="81" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b33">
	<analytic>
		<title level="a" type="main">In silico research in the era of cloud computing</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">T</forename>
				<surname>Dudley</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">A</forename>
				<forename type="middle">J</forename>
				<surname>Butte</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1181" to="1185" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b34">
	<analytic>
		<title level="a" type="main">Identification and analysis of error types in high-throughput genotyping</title>
		<author>
			<persName>
				<forename type="first">K</forename>
				<forename type="middle">R</forename>
				<surname>Ewen</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Hum. Genet</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="727" to="736" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b35">
	<analytic>
		<title level="a" type="main">Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations</title>
		<author>
			<persName>
				<forename type="first">P</forename>
				<forename type="middle">B</forename>
				<surname>Ferrell</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">H</forename>
				<forename type="middle">L</forename>
				<surname>Mcleod</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1543" to="1546" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b36">
	<analytic>
		<title level="a" type="main">PMUT: a web-based tool for the annotation of pathological mutations on proteins</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<surname>Ferrer-Costa</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="3176" to="3178" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b37">
	<analytic>
		<title level="a" type="main">Pharmacogenetics–pivotal to the future of the biopharmaceutical industry</title>
		<author>
			<persName>
				<forename type="first">E</forename>
				<surname>Foot</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Discov. Today</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="325" to="327" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b38">
	<analytic>
		<title level="a" type="main">Human genetic variation and its contribution to complex traits</title>
		<author>
			<persName>
				<forename type="first">K</forename>
				<forename type="middle">A</forename>
				<surname>Frazer</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Genet</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="241" to="251" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b39">
	<analytic>
		<title level="a" type="main">Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues</title>
		<author>
			<persName>
				<forename type="first">B</forename>
				<forename type="middle">F</forename>
				<surname>Gage</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">L</forename>
				<forename type="middle">J</forename>
				<surname>Lesko</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Thromb. Thrombolysis</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="45" to="51" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b40">
	<analytic>
		<title level="a" type="main">PACdb: a database for cell-based pharmacogenomics</title>
		<author>
			<persName>
				<forename type="first">E</forename>
				<forename type="middle">R</forename>
				<surname>Gamazon</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenet. Genomics</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="269" to="273" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b41">
	<analytic>
		<title level="a" type="main">Part I: Milestones in personalised medicine–imatinib</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<surname>Gambacorti-Passerini</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">600</biblScope>
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b42">
	<analytic>
		<title level="a" type="main">Recent progress in automatically extracting information from the pharmacogenomic literature</title>
		<author>
			<persName>
				<forename type="first">Y</forename>
				<surname>Garten</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1467" to="1489" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b43">
	<analytic>
		<title level="a" type="main">The pharmacogenetics research network: from SNP discovery to clinical drug response</title>
		<author>
			<persName>
				<forename type="first">K</forename>
				<forename type="middle">M</forename>
				<surname>Giacomini</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Pharmacol. Ther</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="328" to="345" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b44">
	<analytic>
		<title level="a" type="main">Genomic and personalized medicine: foundations and applications</title>
		<author>
			<persName>
				<forename type="first">G</forename>
				<forename type="middle">S</forename>
				<surname>Ginsburg</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">H</forename>
				<forename type="middle">F</forename>
				<surname>Willard</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transl. Res</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="277" to="287" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b45">
	<analytic>
		<title level="a" type="main">The human disease network</title>
		<author>
			<persName>
				<forename type="first">K.-I</forename>
				<surname>Goh</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proc. Natl Acad. Sci. USA</title>
		<meeting>. Natl Acad. Sci. USA</meeting>
		<imprint>
			<date type="published" when="2007" />
			<biblScope unit="page" from="8685" to="8690" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b46">
	<analytic>
		<title level="a" type="main">Rosiglitazone monotherapy in mild-to-moderate alzheimer&apos;s disease: results from a randomized, double-blind, placebo-controlled phase III study</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<surname>Gold</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dement. Geriatr. Cogn. Disord</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="131" to="146" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b47">
	<analytic>
		<title level="a" type="main">A map of human genome variation from population-scale sequencing</title>
		<author>
			<persName>
				<forename type="first">Project</forename>
				<surname>1000 Genomes</surname>
			</persName>
		</author>
		<author>
			<persName>
				<surname>Consortium</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">467</biblScope>
			<biblScope unit="page" from="1061" to="1073" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b48">
	<analytic>
		<title level="a" type="main">Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions</title>
		<author>
			<persName>
				<forename type="first">L</forename>
				<forename type="middle">W</forename>
				<surname>Hahn</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="376" to="382" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b49">
	<analytic>
		<title level="a" type="main">Generating genome-scale candidate gene lists for pharmacogenomics</title>
		<author>
			<persName>
				<forename type="first">N</forename>
				<forename type="middle">T</forename>
				<surname>Hansen</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Pharmacol. Ther</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="183" to="189" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b50">
	<analytic>
		<title level="a" type="main">Genetic variations in HLA-B region and hypersensitivity reactions to abacavir</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<surname>Hetherington</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page" from="1121" to="1122" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b51">
	<analytic>
		<title level="a" type="main">Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">K</forename>
				<surname>Higashi</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">287</biblScope>
			<biblScope unit="page" from="1690" to="1698" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b52">
	<analytic>
		<title level="a" type="main">Potential etiologic and functional implications of genomewide association loci for human diseases and traits</title>
		<author>
			<persName>
				<forename type="first">L</forename>
				<forename type="middle">A</forename>
				<surname>Hindorff</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proc. Natl Acad. Sci. USA</title>
		<meeting>. Natl Acad. Sci. USA</meeting>
		<imprint>
			<date type="published" when="2009" />
			<biblScope unit="page" from="9362" to="9367" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b53">
	<analytic>
		<title level="a" type="main">Network pharmacology</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Hopkins</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1110" to="1111" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b54">
	<analytic>
		<title level="a" type="main">Trastuzumab–mechanism of action and use in clinical practice</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<forename type="middle">A</forename>
				<surname>Hudis</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="page" from="39" to="51" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b55">
	<analytic>
		<title level="a" type="main">Estimation of the warfarin dose with clinical and pharmacogenetic data</title>
		<author>
			<persName>
				<forename type="first">International</forename>
				<surname>Warfarin</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">Pharmacogenetics</forename>
				<surname>Consortium</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="page" from="753" to="764" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b56">
	<analytic>
		<title level="a" type="main">CanPredict: a computational tool for predicting cancerassociated missense mutations</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">S</forename>
				<surname>Kaminker</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="595" to="598" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b57">
	<analytic>
		<title level="a" type="main">Next generation tools for the annotation of human SNPs</title>
		<author>
			<persName>
				<forename type="first">R</forename>
				<surname>Karchin</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brief. Bioinform</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="35" to="52" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b58">
	<analytic>
		<title level="a" type="main">LS-SNP: large-scale annotation of coding non-synonymous SNPs based on multiple information sources</title>
		<author>
			<persName>
				<forename type="first">R</forename>
				<surname>Karchin</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2814" to="2820" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b59">
	<analytic>
		<title level="a" type="main">Variation in transcription factor binding among humans</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<surname>Kasowski</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="page" from="232" to="235" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b60">
	<analytic>
		<title level="a" type="main">Relating protein pharmacology by ligand chemistry</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<surname>Keiser</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="197" to="206" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b61">
	<analytic>
		<title level="a" type="main">Predicting new molecular targets for known drugs</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">J</forename>
				<surname>Keiser</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">462</biblScope>
			<biblScope unit="page" from="175" to="181" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b62">
	<analytic>
		<title level="a" type="main">BLAT–the BLAST-like alignment tool</title>
		<author>
			<persName>
				<forename type="first">W</forename>
				<forename type="middle">J</forename>
				<surname>Kent</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="656" to="664" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b63">
	<analytic>
		<title level="a" type="main">Systems biology: an approach</title>
		<author>
			<persName>
				<forename type="first">P</forename>
				<surname>Kohl</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Pharmacol. Therap</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="25" to="33" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b64">
	<analytic>
		<title level="a" type="main">A comparative study of machine-learning methods to predict the effects of single nucleotide polymorphisms on protein function</title>
		<author>
			<persName>
				<forename type="first">V</forename>
				<forename type="middle">G</forename>
				<surname>Krishnan</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">D</forename>
				<forename type="middle">R</forename>
				<surname>Westhead</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="2199" to="2209" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b65">
	<analytic>
		<title level="a" type="main">Predicting unobserved phenotypes for complex traits from wholegenome SNP data</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<forename type="middle">H</forename>
				<surname>Lee</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Genet</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b66">
	<analytic>
		<title level="a" type="main">Fast and accurate short read alignment with BurrowsWheeler transform</title>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Li</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">R</forename>
				<surname>Durbin</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1754" to="1760" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b67">
	<analytic>
		<title level="a" type="main">A survey of sequence alignment algorithms for nextgeneration sequencing</title>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Li</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">N</forename>
				<surname>Homer</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brief. Bioinform</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="473" to="483" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b68">
	<analytic>
		<title level="a" type="main">Automated inference of molecular mechanisms of disease from amino acid substitutions</title>
		<author>
			<persName>
				<forename type="first">B</forename>
				<surname>Li</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="2744" to="2750" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b69">
	<analytic>
		<title level="a" type="main">Warfarin pharmacogenetics</title>
		<author>
			<persName>
				<forename type="first">N</forename>
				<forename type="middle">A</forename>
				<surname>Limdi</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">D</forename>
				<forename type="middle">L</forename>
				<surname>Veenstra</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacotherapy</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1084" to="1097" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b70">
	<analytic>
		<title level="a" type="main">The NCBI dbGaP database of genotypes and phenotypes</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">D</forename>
				<surname>Mailman</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1181" to="1186" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b71">
	<analytic>
		<title level="a" type="main">Finding the missing heritability of complex diseases</title>
		<author>
			<persName>
				<forename type="first">T</forename>
				<forename type="middle">A</forename>
				<surname>Manolio</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">461</biblScope>
			<biblScope unit="page" from="747" to="753" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b72">
	<analytic>
		<title level="a" type="main">An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<forename type="middle">L</forename>
				<surname>Mcguire</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">W</forename>
				<surname>Burke</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">300</biblScope>
			<biblScope unit="page" from="2669" to="2671" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b73">
	<analytic>
		<title level="a" type="main">Bioinformatics approaches and resources for single nucleotide polymorphism functional analysis</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<surname>Mooney</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brief. Bioinform</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="44" to="56" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b74">
	<analytic>
		<title level="a" type="main">Bioinformatics challenges for genome-wide association studies</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">H</forename>
				<surname>Moore</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="445" to="455" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b75">
	<analytic>
		<title level="a" type="main">Novel methods for detecting epistasis in pharmacogenomics studies</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<forename type="middle">A</forename>
				<surname>Motsinger</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1229" to="1241" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b76">
	<analytic>
		<title level="a" type="main">Genome-wide association studies in pharmacogenomics: successes and lessons</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<forename type="middle">A</forename>
				<surname>Motsinger-Reif</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenet. Genomics</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b77">
	<analytic>
		<title level="a" type="main">SIFT: predicting amino acid changes that affect protein function</title>
		<author>
			<persName>
				<forename type="first">P</forename>
				<forename type="middle">C</forename>
				<surname>Ng</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">S</forename>
				<surname>Henikoff</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="3812" to="3814" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b78">
	<analytic>
		<title level="a" type="main">Exome sequencing identifies the cause of a mendelian disorder</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<forename type="middle">B</forename>
				<surname>Ng</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="30" to="35" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b79">
	<analytic>
		<title level="a" type="main">The SNP ratio test: pathway analysis of genome-wide association datasets</title>
		<author>
			<persName>
				<forename type="first">O</forename>
				<surname>&apos;dushlaine</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">C</forename>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="2762" to="2763" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b80">
	<analytic>
		<title level="a" type="main">Benefits of pharmacogenomics in drug developmentearlier launch of drugs and less adverse events</title>
		<author>
			<persName>
				<forename type="first">W</forename>
				<surname>Ohashi</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Tanaka</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Syst</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="701" to="707" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b81">
	<analytic>
		<title level="a" type="main">Global mapping of pharmacological space</title>
		<author>
			<persName>
				<forename type="first">G</forename>
				<forename type="middle">V</forename>
				<surname>Paolini</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="805" to="815" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b82">
	<analytic>
		<title level="a" type="main">G2D: a tool for mining genes associated with disease</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<surname>Perez-Iratxeta</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Genet</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">45</biblScope>
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b83">
	<analytic>
		<title level="a" type="main">Population genetic inference from genomic sequence variation</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">E</forename>
				<surname>Pool</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="291" to="300" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b84">
	<analytic>
		<title level="a" type="main">An integrated approach to inferring gene-disease associations in humans</title>
		<author>
			<persName>
				<forename type="first">P</forename>
				<surname>Radivojac</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proteins</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1030" to="1037" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b85">
	<analytic>
		<title level="a" type="main">Human non-synonymous SNPs: server and survey</title>
		<author>
			<persName>
				<forename type="first">V</forename>
				<surname>Ramensky</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="3894" to="3900" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b86">
	<analytic>
		<title level="a" type="main">Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">J</forename>
				<surname>Rieder</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="page" from="2285" to="2293" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b87">
	<analytic>
		<title level="a" type="main">Development of a large-scale de-identified DNA Biobank to enable personalized medicine</title>
		<author>
			<persName>
				<forename type="first">D</forename>
				<surname>Roden</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Pharmacol. Ther</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="362" to="369" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b88">
	<analytic>
		<title level="a" type="main">Pharmacogenetics and drug development: the path to safer and more effective drugs</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<forename type="middle">D</forename>
				<surname>Roses</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Genet</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="645" to="656" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b89">
	<analytic>
		<title level="a" type="main">The medical and economic roles of pipeline pharmacogenetics: Alzheimer&apos;s disease as a model of efficacy and HLA-B(*)5701 as a model of safety</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<forename type="middle">D</forename>
				<surname>Roses</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="6" to="17" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b90">
	<analytic>
		<title level="a" type="main">Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<surname>Rost</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">427</biblScope>
			<biblScope unit="page" from="537" to="541" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b91">
	<analytic>
		<title level="a" type="main">A review of feature selection techniques in bioinformatics</title>
		<author>
			<persName>
				<forename type="first">Y</forename>
				<surname>Saeys</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2507" to="2517" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b92">
	<analytic>
		<title level="a" type="main">Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9</title>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Sagreiya</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenet. Genomics</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="407" to="413" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b93">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b94">
	<monogr>
		<title/>
		<author>
			<persName>
				<surname>Page</surname>
			</persName>
		</author>
		<imprint>
			<biblScope unit="page" from="1748" to="1741" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b95">
	<monogr>
		<title/>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Fernald</surname>
			</persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b96">
	<analytic>
		<title level="a" type="main">Improving disease gene prioritization using the semantic similarity of Gene Ontology terms</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Schlicker</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="561" to="567" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b97">
	<analytic>
		<title level="a" type="main">The FoldX web server: an online force field</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<surname>Schymkowitz</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="382" to="388" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b98">
	<analytic>
		<title level="a" type="main">Next-generation DNA sequencing</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<surname>Shendure</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Ji</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1135" to="1145" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b99">
	<analytic>
		<title level="a" type="main">dbSNP: the NCBI database of genetic variation</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<forename type="middle">T</forename>
				<surname>Sherry</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="308" to="311" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b100">
	<analytic>
		<title level="a" type="main">Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<forename type="middle">R</forename>
				<surname>Shuldiner</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">302</biblScope>
			<biblScope unit="page" from="849" to="857" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b101">
	<analytic>
		<title level="a" type="main">Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<forename type="middle">R</forename>
				<surname>Shuldiner</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="page" from="849" to="857" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b102">
	<analytic>
		<title level="a" type="main">Identification of common molecular subsequences</title>
		<author>
			<persName>
				<forename type="first">T</forename>
				<forename type="middle">F</forename>
				<surname>Smith</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">S</forename>
				<surname>Waterman</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Mol. Biol</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="195" to="197" />
			<date type="published" when="1981" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b103">
	<analytic>
		<title level="a" type="main">Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">L</forename>
				<surname>Soares</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Mol. Genet</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="543" to="553" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b104">
	<analytic>
		<title level="a" type="main">A comprehensive evaluation of multicategory classification methods for microarray gene expression cancer diagnosis</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Statnikov</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="631" to="643" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b105">
	<analytic>
		<title level="a" type="main">Multiple locus linkage analysis of genomewide expression in yeast</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">D</forename>
				<surname>Storey</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Biol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">267</biblScope>
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b106">
	<analytic>
		<title level="a" type="main">Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Subramanian</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proc. Natl Acad. Sci. USA</title>
		<meeting>. Natl Acad. Sci. USA</meeting>
		<imprint>
			<date type="published" when="2005" />
			<biblScope unit="page">15545</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b107">
	<analytic>
		<title level="a" type="main">In silico analysis of missense substitutions using sequencealignment based methods</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<forename type="middle">V</forename>
				<surname>Tavtigian</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Mutat</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1327" to="1336" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b108">
	<analytic>
		<title level="a" type="main">Coding single-nucleotide polymorphisms associated with complex vs. Mendelian disease: evolutionary evidence for differences in molecular effects</title>
		<author>
			<persName>
				<forename type="first">P</forename>
				<forename type="middle">D</forename>
				<surname>Thomas</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Kejariwal</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proc. Natl Acad. Sci. USA</title>
		<meeting>. Natl Acad. Sci. USA</meeting>
		<imprint>
			<date type="published" when="2004" />
			<biblScope unit="page" from="15398" to="15403" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b109">
	<analytic>
		<title level="a" type="main">PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification</title>
		<author>
			<persName>
				<forename type="first">P</forename>
				<forename type="middle">D</forename>
				<surname>Thomas</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="334" to="341" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b110">
	<analytic>
		<title level="a" type="main">Pharmacogenomics and bioinformatics: PharmGKB</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<forename type="middle">F</forename>
				<surname>Thorn</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="501" to="505" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b111">
	<analytic>
		<title level="a" type="main">Performance of mutation pathogenicity prediction methods on missense variants</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<surname>Thusberg</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Mutat</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="358" to="368" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b112">
	<analytic>
		<title level="a" type="main">A guide to web tools to prioritize candidate genes</title>
		<author>
			<persName>
				<forename type="first">L</forename>
				<surname>Tranchevent</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brief. Bioinformat</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="22" to="32" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b113">
	<analytic>
		<title level="a" type="main">ENDEAVOUR update: a web resource for gene prioritization in multiple species</title>
		<author>
			<persName>
				<forename type="first">L</forename>
				<forename type="middle">C</forename>
				<surname>Tranchevent</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="377" to="384" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b114">
	<analytic>
		<title level="a" type="main">A text-mining analysis of the human phenome</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">A</forename>
				<surname>Van Driel</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Hum. Genet</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="535" to="542" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b115">
	<analytic>
		<title level="a" type="main">MuD: an interactive web server for the prediction of nonneutral substitutions using protein structural data</title>
		<author>
			<persName>
				<forename type="first">G</forename>
				<surname>Wainreb</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="523" to="528" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note>Suppl. .</note>
</biblStruct>

<biblStruct   xml:id="b116">
	<analytic>
		<title level="a" type="main">Pathway-based approaches for analysis of genomewide association studies</title>
		<author>
			<persName>
				<forename type="first">K</forename>
				<surname>Wang</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Hum. Genet</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="1278" to="1283" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b117">
	<analytic>
		<title level="a" type="main">Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase</title>
		<author>
			<persName>
				<forename type="first">R</forename>
				<surname>Weinshilboum</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Metab. Dispos</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="601" to="605" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b118">
	<analytic>
		<title level="a" type="main">From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics</title>
		<author>
			<persName>
				<forename type="first">B</forename>
				<surname>Wilffert</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Clinical Pharmacy</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="3" to="9" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b119">
	<analytic>
		<title level="a" type="main">Combinatorial pharmacogenetics</title>
		<author>
			<persName>
				<forename type="first">R</forename>
				<forename type="middle">A</forename>
				<surname>Wilke</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Drug Discov</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="911" to="918" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b120">
	<analytic>
		<title level="a" type="main">Multilocus analysis of hypertension: a hierarchical approach</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<forename type="middle">M</forename>
				<surname>Williams</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Hered</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="28" to="38" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b121">
	<analytic>
		<title level="a" type="main">Genomic features defining exonic variants that modulate splicing</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Woolfe</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Biol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">20</biblScope>
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b122">
	<analytic>
		<title level="a" type="main">Prediction of individual genetic risk to disease from genomewide association studies</title>
		<author>
			<persName>
				<forename type="first">N</forename>
				<forename type="middle">R</forename>
				<surname>Wray</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1520" to="1528" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b123">
	<analytic>
		<title level="a" type="main">Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls</title>
		<author>
			<persName>
				<forename type="first">Wtcc</forename>
				<surname>Consortium</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">447</biblScope>
			<biblScope unit="page" from="661" to="678" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b124">
	<analytic>
		<title level="a" type="main">Statistical power of model selection strategies for genomewide association studies</title>
		<author>
			<persName>
				<forename type="first">Z</forename>
				<surname>Wu</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Zhao</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Genet</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">1000582</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b125">
	<analytic>
		<title level="a" type="main">Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action</title>
		<author>
			<persName>
				<forename type="first">D</forename>
				<forename type="middle">K</forename>
				<surname>Wysowski</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch. Intern. Med</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="1414" to="1419" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b126">
	<analytic>
		<title level="a" type="main">Principal component analysis for clustering gene expression data</title>
		<author>
			<persName>
				<forename type="first">K</forename>
				<forename type="middle">Y</forename>
				<surname>Yeung</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">W</forename>
				<forename type="middle">L</forename>
				<surname>Ruzzo</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="763" to="774" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b127">
	<analytic>
		<title level="a" type="main">Drug-target network</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">A</forename>
				<surname>Yildirim</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1119" to="1126" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b128">
	<analytic>
		<title level="a" type="main">The promise and reality of personal genomics</title>
		<author>
			<persName>
				<forename type="first">B</forename>
				<surname>Yngvadottir</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Biol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">237</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b129">
	<analytic>
		<title level="a" type="main">Pathway analysis by adaptive combination of P-values</title>
		<author>
			<persName>
				<forename type="first">K</forename>
				<surname>Yu</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genet. Epidemiol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="700" to="709" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b130">
	<analytic>
		<title level="a" type="main">Identification and analysis of deleterious human SNPs</title>
		<author>
			<persName>
				<forename type="first">P</forename>
				<surname>Yue</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">J</forename>
				<surname>Moult</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Mol. Biol</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="page" from="1263" to="1274" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b131">
	<analytic>
		<title level="a" type="main">Use of cell lines in the investigation of pharmacogenetic loci</title>
		<author>
			<persName>
				<forename type="first">W</forename>
				<surname>Zhang</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">E</forename>
				<surname>Dolan</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Pharm. Des</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="3782" to="3795" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b132">
	<analytic>
		<title level="a" type="main">Patterns of nucleotide substitution, insertion and deletion in the human genome inferred from pseudogenes</title>
		<author>
			<persName>
				<forename type="first">Z</forename>
				<surname>Zhang</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">M</forename>
				<surname>Gerstein</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="5338" to="5348" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b133">
	<analytic>
		<title level="a" type="main">Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction</title>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Zhou</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">Y</forename>
				<surname>Zhou</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Protein Sci</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="2714" to="2726" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>